Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Pulse Biosciences ( (PLSE) ).
On September 2, 2025, Pulse Biosciences announced the first successful procedures in its PRECISE-BTN study, a multicenter clinical trial using its nsPFA Percutaneous Electrode System for treating benign thyroid nodules. This milestone signifies progress in demonstrating the safety and efficacy of the technology in reducing symptoms while preserving thyroid function, with the study aiming to treat up to 50 patients across four sites and evaluating outcomes over a year.
The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
Pulse Biosciences receives a low overall score due to persistent financial challenges such as continuous losses and cash burn. While technical indicators show some positive momentum, the valuation remains unattractive due to negative earnings. The earnings call provided a balanced view with notable advancements in technology and strengthened finances, but increased operational costs remain a concern. The CFO appointment is a positive strategic move but does not significantly affect the overall score.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences is a bioelectric medicine company focused on health innovation, aiming to enhance patient quality of life through its proprietary CellFX nsPFA technology. This technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue, with potential applications in treating atrial fibrillation and surgical soft tissue ablation.
Average Trading Volume: 171,998
Technical Sentiment Signal: Buy
Current Market Cap: $1.05B
For a thorough assessment of PLSE stock, go to TipRanks’ Stock Analysis page.